Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study

Correction to: BMC Cancer 21, 248 (2021)

https://doi.org/10.1186/s12885-021-07939-w

Following publication of the original article [1], an error was discovered in table 3 “Logistic regression model for use of antidepressants, sedatives and anti-epileptics, respectively, at one year following index date, for patients with LGG.” In this table, the numbers presented for anti-epileptics are equal to the numbers for the sedatives. There has been a copy error and numbers need to be adjusted. The new results do not change the conclusions. The updated table 3 is given below and the changed values are displayed in bold typeface.

Covariate	Univariable		Multivariable
	OR (95 % CI)	p-value	OR (95 % CI)	p-value
ANTIDEPRESSANTS
Index year (per year)	1.22 (1.07-1.39)	0.002**	1.31 (1.11-1.55)	0.002**
Female (vs. male)	2.99 (1.60-5.60)	0.001**	3.41 (1.71-6.80)	0.001**
Age (per year)	1.02 (1.00-1.05)	0.027*	1.02 (1.00-1.05)	0.11
Income (per 100.000 SEK)	0.96 (0.76-1.20)	0.69	1.07 (0.83-1.39)	0.60
Higher education (vs. lower education)	0.94 (0.78-1.15)	0.56	0.97 (0.78-1.21)	0.78
History of depression	7.61 (3.88-14.94)	<0.001***	6.12 (2.96-12.63)	<0.001***
Use of antidepressants preoperatively	14.15 (5.88-34.08),	<0.001***
Elixhauser comorbidity index (0, 1, 2, >3)	1.33 (0.96-1.84)	0.09	1.09 (0.75-1.59)	0.65
Functional level (per WHO performance status category)	0.98 (0.92-1.03)	0.38	0.96 (0.88-1.06)	0.42
Tumour size (6)	1.08 (0.96-1-21)	0.22	0.92 (0.79-1.07)	0.30
SEDATIVES
Index year (per year)	1.13 (0.99-1.29)	0.07	1.12 (0.97-1.30)	0.14
Female (vs. male)	1.23 (0.66-2.30)	0.51	1.13 (0.58-2.19)	0.73
Age (per year)	1.02 (1.00-1.04)	0.09	1.02 (0.99-1.04)	0.24
Income (per 100.000 SEK)	0.87 (0.67-1.13)	0.30	0.90 (0.62-1.22)	0.49
Higher education (vs. lower education)	0.81 (0.66-1.00)	0.05	0.90 (0.71-1.13)	0.35
History of anxiety and/or sleeping difficulties	2.58 (1.36-4.90)	0.004**	2.14 (1.09-4.20)	0.027*
use of sedatives preoperatively	3.05 (1.60-5.82),	<0.001***
Elixhauser comorbidity index (0, 1, 2, >3)	1.37 (0.98-1.92)	0.07	1.17 (0.80-1.70)	0.41
Functional level (per WHO performance status category)	0.97 (0.91-1.04)	0.42	0.97 (0.89-1.05)	0.43
Tumour size (6)	1.09 (0.97-1.23)	0.17	1.00 (0.87-1.16)	0.98
ANTI-EPILEPTICS
Index year (per year)	1.00 (0.92-1.08)	1.00	1.01 (0.92-1.12)	0.83
Female (vs. male)	1.11 (0.75-1.64)	0.60	1.13 (0.71-1.82)	0.60
Age (per year)	1.00 (0.98-1.01)	0.64	1.00 (0.98-1.02)	0.93
Income (per 100.000 SEK)	1.02 (0.88-1.18)	0.79	0.94 (0.79-1.12)	0.49
Higher education (vs. lower education)	1.04 (0.92-1.19)	0.53	1.04 (0.87-1.23)	0.69
History of AED-use and/or seizure/epilepsy preoperatively	12.16 (7.15-20.69)	<0.001***	12.98 (7.53-22.37)	<0.001***
Elixhauser comorbidity index (0, 1, 2, >3)	0.90 (0.69-1.17)	0.42	0.93 (0.67-1.28)	0.64
Functional level (per WHO performance status category)	1.00 (0.99-1.01)	0.85	1.00 (0.98-1.01)	0.85
Tumour size (6)	1.03 (0.94-1.12)	0.58	1.00 (0.90-1.13)	0.94
Biopsy vs resection	0.78 (0.49-1.25)	0.30	0.67 (0.38 –1.19)	0.17

*p <0.05, **p < 0.01, ***p < 0.001